Myeloid-Derived Suppressor Cells
"Myeloid-Derived Suppressor Cells" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous, immature population of myeloid cells that can suppress the activity of T-CELLS and NATURAL KILLER CELLS in the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNE RESPONSE. They play important roles in ONCOGENESIS; INFLAMMATION; and INFECTION.
| Descriptor ID |
D000072737
|
| MeSH Number(s) |
A11.627.817
|
| Concept/Terms |
Myeloid-Derived Suppressor Cells- Myeloid-Derived Suppressor Cells
- Cell, Myeloid-Derived Suppressor
- Cells, Myeloid-Derived Suppressor
- Myeloid Derived Suppressor Cells
- Myeloid-Derived Suppressor Cell
- Suppressor Cell, Myeloid-Derived
- Suppressor Cells, Myeloid-Derived
- MDSCs
|
Below are MeSH descriptors whose meaning is more general than "Myeloid-Derived Suppressor Cells".
Below are MeSH descriptors whose meaning is more specific than "Myeloid-Derived Suppressor Cells".
This graph shows the total number of publications written about "Myeloid-Derived Suppressor Cells" by people in this website by year, and whether "Myeloid-Derived Suppressor Cells" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 1 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2025 | 2 | 0 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloid-Derived Suppressor Cells" by people in Profiles.
-
Towards a map of the immune system manipulation network by Trypanosoma cruzi. Front Cell Infect Microbiol. 2025; 15:1711520.
-
Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease. Blood. 2025 Oct 23; 146(17):2047-2062.
-
NLRP3 Inflammasome Activation Expands the Immunosuppressive Myeloid Stroma and Antagonizes the Therapeutic Benefit of STING Activation in Glioblastoma. Cancer Res Commun. 2025 Jun 01; 5(6):960-972.
-
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
-
Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2022 04; 28(4):203.e1-203.e7.
-
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021 11; 9(11).
-
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. J Immunother Cancer. 2021 08; 9(8).
-
CD8+ T cells inhibit metastasis and CXCL4 regulates its function. Br J Cancer. 2021 07; 125(2):176-189.
-
TIME Is a Great Healer-Targeting Myeloid Cells in the Tumor Immune Microenvironment to Improve Triple-Negative Breast Cancer Outcomes. Cells. 2020 12 23; 10(1).
-
Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific. Oncogene. 2021 01; 40(3):693-704.